Structure via PubChem · Public domain (PubChem)
samidorphan
Sign in to saveAlso known as ALKS-33
Samidorphan (, ) is an opioid antagonist that in the form of olanzapine/samidorphan (sold as Lybalvi) is used in the treatment of schizophrenia and bipolar disorder. Samidorphan reduces the weight gain associated with olanzapine. Samidorphan is taken by mouth.
Chemical data
- Formula
- C21H26N2O4
- Molecular weight
- 370.4 g/mol
- IUPAC name
- (1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dihydroxy-13-oxo-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4-carboxamide
- SMILES
- C1CC1CN2CC[C@]34CC(=O)CC[C@]3([C@H]2CC5=C4C(=C(C=C5)C(=O)N)O)O
- InChIKey
- RYIDHLJADOKWFM-MAODMQOUSA-N
- XLogP
- 1.1
- Polar surface area
- 104 Ų
- H-bond donors
- 3
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2021
- Admin. routes
- oral
- Indications
- eating disorder, schizophrenia, alcohol dependence, cocaine abuse
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 370.189
Show 4 more facts
- chemical formula
- C₂₁H₂₆N₂O₄
- isomeric SMILES
- C1CC1CN2CC[C@]34CC(=O)CC[C@]3([C@H]2CC5=C4C(=C(C=C5)C(=O)N)O)O
- canonical SMILES
- C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O
- Commons category
- Samidorphan
Sources (2)
via Wikidata · CC0
~4 min read
Encyclopedic overview
9 sectionsContents
- Development
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- References
- See also
- External links
Samidorphan (, ) is an opioid antagonist that in the form of olanzapine/samidorphan (sold as Lybalvi) is used in the treatment of schizophrenia and bipolar disorder. Samidorphan reduces the weight gain associated with olanzapine. Samidorphan is taken by mouth.
Samidorphan was under development as a standalone medication for various indications but has been discontinued. Buprenorphine/samidorphan for the treatment of major depressive disorder was rejected by the US Food and Drug Administration (FDA) due to insufficient evidence of effectiveness, but remains in preregistration as of September 2021. Development of baclofen/samidorphan has also been discontinued.
Excerpted from Wikipedia’s “samidorphan” article, available under the CC BY-SA 4.0 licence.